Abstract
Background Titin truncating variants (TTNtv) have been associated with several forms of myopathies and/or cardiomyopathies. In homozygosity or in compound heterozygosity they cause a wide spectrum of recessive phenotypes with a congenital or childhood onset. Most recessive phenotypes showing a congenital or childhood onset have been described in subjects carrying biallelic TTNtv in specific exons. However, TTN is not yet included in many NGS panels for congenital musculoskeletal anomalies and dysmorphisms, and karyotype or chromosomal microarray analyses are often the only tests performed when prenatal anomalies are identified. Thereby, many cases caused by TTN defects might be missed in the diagnostic evaluations. In this study, we aimed to dissect the most severe end of the titinopathies spectrum.
Methods We performed a retrospective study analysing an international cohort of 93 published and 10 unpublished cases carrying biallelic TTNtv.
Results We identified recurrent clinical features in antenatal and congenital recessive titinopathies, including fetal akinesia, arthrogryposis, facial dysmorphisms, joint, bone, and heart anomalies resembling complex, syndromic phenotypes.
Conclusion We suggest TTN to be carefully evaluated in any diagnostic process involving patients with the mentioned signs. This step will be essential to improve diagnostic performance, expand our knowledge, and optimize prenatal genetic counseling.
Key message Truncating variants in the titin gene (TTN) have been associated with a large spectrum of skeletal muscle diseases with or without cardiac involvement. The current work demonstrates that truncating biallelic variants in specific exons of TTN result in severe developmental anomalies, affecting not only the muscular systems but also bone, heart, and other organs, with a quite high rate of miscarriages and dysmorphisms. Thereby, we suggest TTN variants to be carefully evaluated in any diagnostic process involving patients with the mentioned signs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Marco Savarese was funded by the Academy of Finland and Sydantutkimussaatio, Bjarne Udd was funded by the Academy of Finland and the European Joint Program for Rare Disease (EJPRD)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the patients or their legal guardians provided written informed consent to their referring clinician. The study was performed in accordance with the Declaration of Helsinki. Ethical approval was obtained through the institutional review board HUS:195/13/03/00/11 ((Helsingin Yliopistollinen Sairaala - Hospital District of Helsinki and Uusimaa).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
